phoxim: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9570290 |
| CHEMBL ID | 1906626 |
| SCHEMBL ID | 591312 |
| MeSH ID | M0044110 |
| Synonym |
|---|
| valexon |
| bayer 77488 |
| caswell no. 902l |
| glyoxylonitrile, phenyl-, oxime, o,o-diethyl phosphorothioate |
| sra 7502 |
| 4-ethoxy-7-phenyl-3,5-dioxa-6-aza-4-phosphaoct-6-ene-8-nitrile 4-sulfide |
| bay sra 7502 |
| o,o-diaethyl-o-(alpha-cyano-benzylidenamino)-monothiophosphat [german] |
| epa pesticide chemical code 598800 |
| volaton |
| baythion |
| phoxime [iso-french] |
| 2-(diethoxyphosphinothioyloxyimino)-2-phenylacetonitrile |
| phoximum [inn-latin] |
| phoxim [bsi:iso] |
| ent 27488 |
| foxima [inn-spanish] |
| oms 1170 |
| o,o-diethyl phosphorothioate, o-ester with phenylglyoxylonitrile oxime |
| ai3-27448 |
| einecs 238-887-3 |
| phoxim [inn:ban] |
| bay 5621 |
| benzeneacetonitrile, alpha-(((diethoxyphosphinothioyl)oxy)imino)- |
| valexone |
| b 77488 |
| o,o-diethyl alpha-cyanobenzylideneamino-oxyphosphonothioate |
| bay 77488 |
| o,o-diaethyl-o-(alpha-cyanbenzyliden-amino)-thionphosphat [german] |
| phenylglyoxylonitrile oxime o,o-diethyl phosphorothioate |
| benzoyl cyanide o-(diethoxyphosphinothioyl)oxime |
| phoxime [inn-french] |
| (diethoxy-thiophosphoryloxyimino)-phenyl acetonitrile |
| diethoxyphosphinothioyloxyimino(phenyl)acetonitrile |
| 3,5-dioxa-6-aza-4-phosphaoct-6-ene-8-nitrile, 4-ethoxy-7-phenyl-, 4-sulfide |
| phoxim |
| NCGC00166158-01 |
| NCGC00163705-02 |
| phoxim (ban) |
| sebacil [veterinary] (tn) |
| D08373 |
| inchi=1/c12h15n2o3ps/c1-3-15-18(19,16-4-2)17-14-12(10-13)11-8-6-5-7-9-11/h5-9h,3-4h2,1-2h3/b14-12+ |
| atrohalucmtwtb-wymlvpiesa- |
| A808742 |
| (2z)-2-diethoxyphosphinothioyloxyimino-2-phenylacetonitrile |
| (2z)-2-diethoxyphosphinothioyloxyimino-2-phenyl-ethanenitrile |
| C18757 |
| bayer 9053 |
| unii-6f5v775vpo |
| phoximum |
| o,o-diaethyl-o-(alpha-cyano-benzylidenamino)-monothiophosphat |
| o,o-diaethyl-o-(alpha-cyanbenzyliden-amino)-thionphosphat |
| foxima |
| NCGC00255304-01 |
| dtxcid6014324 |
| tox21_301580 |
| cas-14816-18-3 |
| tox21_113357 |
| CHEMBL1906626 |
| AKOS015915518 |
| SCHEMBL591312 |
| NCGC00166158-02 |
| tox21_113357_1 |
| benzeneacetonitrile, [[(diethoxyphosphinothioyl)oxy]imino]- |
| o,o-diaethyl-o-(.alpha.-cyanbenzyliden-amino)-thionphosphat |
| bayer 5621 |
| 4-ethoxy-7-phenyl-3,5-dioxa-6-aza-4-phosphaoct-6-ene-8-nitril 4-sulfide |
| phoxin |
| .alpha.-(((diethoxyphosphinothioyl)oxy)imino)benzeneacetonitrile |
| benzeneacetonitrile, .alpha.-[[(diethoxyphosphinothioyl)oxy]imino]- |
| o,o-diaethyl-o-(.alpha.-cyano-benzylidenamino)-monothiophosphat |
| o,o-diethyl .alpha.-cyanobenzylideneamino-oxyphosphonothioate |
| glyoxylonitrile, phenyl-, oxime o,o-diethyl phosphorothioate |
| foxim |
| o,o-diethyl-.alpha.-cyanobenzylidineaminooxyphosphonothiate |
| o,o-diethyl o-(.alpha.-cyanobenzylideneamino)phosphorothioate |
| SR-01000883974-1 |
| sr-01000883974 |
| phoxim, pestanal(r), analytical standard |
| phoxim 100 microg/ml in cyclohexane |
| phoxim 10 microg/ml in cyclohexane |
| J-008445 |
| Q27895843 |
| 1ST20170 |
| phoxim 1000 microg/ml in acetone |
| DTXSID80860144 |
| 217075-82-6 |
| AKOS040753538 |
| o,o-diethyl (e)-(((cyano(phenyl)methylene)amino)oxy)phosphonothioate |
| Excerpt | Reference | Relevance |
|---|---|---|
| " While multiple exposure is widely acknowledged, arguments are raised that adverse combined effects might not be evoked by mixtures of substances with dissimilar modes of action and being present at only low concentrations." | ( Mixture toxicity of priority pollutants at no observed effect concentrations (NOECs). Altenburger, R; Consolaro, F; Gramatica, P; Scholze, M; Walter, H, 2002) | 0.31 |
| " The observed synergistic interactions underline the necessity to review soil quality guidelines, which are likely underestimating the adverse combined effects of these compounds." | ( Joint acute toxicity of the herbicide butachlor and three insecticides to the terrestrial earthworm, Eisenia fetida. Cai, L; Cang, T; Chen, C; Liu, X; Wang, Q; Wang, Y; Wu, S; Yu, R, 2016) | 0.43 |
| "Currently, public pay more attention to the adverse effect of organophosphate pesticides on human and animal health and on the environment in developing nations." | ( Effects of phoxim-induced hepatotoxicity on SD rats and the protection of vitamin E. Shan, A; Song, W; Sun, Y; Zhang, J, 2017) | 0.46 |
Sodium bicarbonate combined with ulinastatin can improve the therapeutic effect and reduce complications in the treatment of acute phoxim pesticide poisoning. It has beneficial effects on the recovery of cholinesterase activity.
| Excerpt | Reference | Relevance |
|---|---|---|
| " It is made clear that this method (two-dimensional correlation analysis combined with partial least squares discriminant analysis) is effective to detect directly phoxim in water." | ( Direct detection of phoxim in water by two-dimensional correlation near-infrared spectroscopy combined with partial least squares discriminant analysis. Gu, C; Xiang, B; Xu, J, 2012) | 0.38 |
| "To observe the effect of sodium bicarbonate combined with ulinastatin on cholinesterase activity for patients with acute phoxim pesticide poisoning." | ( [The influence of sodium bicarbonate combined with ulinastatin on cholinesterase activity for patients with acute phoxim pesticide poisoning]. Gao, D; Jian, X; Sun, B; Xiao, L; Yang, L; Zhao, B; Zou, X, 2016) | 0.43 |
| "Sodium bicarbonate combined with ulinastatin can improve the therapeutic effect and reduce complications in the treatment of acute phoxim pesticide poisoning, and have beneficial effects on the recovery of cholinesterase activity." | ( [The influence of sodium bicarbonate combined with ulinastatin on cholinesterase activity for patients with acute phoxim pesticide poisoning]. Gao, D; Jian, X; Sun, B; Xiao, L; Yang, L; Zhao, B; Zou, X, 2016) | 0.43 |
| Excerpt | Reference | Relevance |
|---|---|---|
| ") as 'pour-ons' in a crossover design in order to determine the dermal bioavailability of the OPs." | ( Percutaneous absorption of organophosphorus insecticides in pigs--the influence of different vehicles. Brimer, L; Gyrd-Hansen, N; Rasmussen, F, 1993) | 0.29 |
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
The function of the neuromuscular transmission in rats dosed with phoxim (P), methomyl (M), fenvalerate (F), and mixtures of P+M and P+F was studied. The effects of phoxin at various dosage levels on sperm production and motility in rats were studied.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Good dose-response data were obtained for all three OPs tested, although the instability of phosmet required special precautions concerning the analysis of the agar." | ( Evaluation of an in vitro method for acaricidal effect. Activity of parathion, phosmet and phoxim against Sarcoptes scabiei. Brimer, L; Gyrd-Hansen, N; Henriksen, SA; Rasmussen, F, 1993) | 0.29 |
| "The function of the neuromuscular transmission in rats dosed with phoxim (P), methomyl (M), fenvalerate (F), and mixtures of P+M and P+F was studied by using both the stimulation single fiber electromyography (SSFEMG) and repetitive nerve stimulations (RNS) to determine the single muscle fiber action potential and compound muscle action potential (CMAP) respectively." | ( Repetitive nerve stimulation and stimulation single fiber electromyography studies in rats intoxicated with single or mixed insecticides. He, F; Li, T; Yang, D, 2001) | 0.31 |
| "The effects of phoxim at various dosage levels on sperm production and motility in rats were studied." | ( [Effects of phoxim on sperm production and motility of rats]. Wang, S; Wang, X; Zhan, N, 2000) | 0.31 |
| "Ten rats were dosed with phoxim (1,144 mg/kg) and 5 of them developed myasthenia." | ( [Potential biochemical mechanisms of neuromuscular junction transmission dysfunction induced by organophosphorus insecticides]. He, FS; Li, QS; Niu, Y; Xiao, C; Yu, T, 2003) | 0.32 |
| " The total atropine dosage, total pralidoxime methylchloride dosage and hospitalization days were better than the conventional treatment group, and the differences were statistically significant (P<0." | ( [The influence of sodium bicarbonate combined with ulinastatin on cholinesterase activity for patients with acute phoxim pesticide poisoning]. Gao, D; Jian, X; Sun, B; Xiao, L; Yang, L; Zhao, B; Zou, X, 2016) | 0.43 |
| "With continuous development of pesticide dosage forms, emulsifiable concentrates using large amounts of organic solvents are gradually obsoleted." | ( Microfluidic preparation of a novel phoxim nanoemulsion pesticide against Spodoptera litura. Li, P; Li, ZN; Pan, LH; Sheng, S; Wang, J; Wu, FA; Xu, Y; Zhang, YX; Zhang, ZA, 2022) | 0.72 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| acetylcholinesterase | Homo sapiens (human) | Potency | 26.8821 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395; AID1347397; AID1347398; AID1347399 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 27.5357 | 0.1737 | 34.3047 | 61.8120 | AID1346859 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 27.5357 | 0.1737 | 34.3047 | 61.8120 | AID1346859 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 5.3080 | 0.0007 | 14.5928 | 83.7951 | AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 24.5815 | 0.0002 | 21.2231 | 8,912.5098 | AID588516; AID743036; AID743042 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 26.1602 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 67.9649 | 0.0004 | 17.9460 | 75.1148 | AID1346784; AID1346795 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 1.5487 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 26.8325 | 0.0002 | 14.3764 | 60.0339 | AID720691 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 29.8493 | 0.0030 | 41.6115 | 22,387.1992 | AID1159553 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 12.2097 | 0.0008 | 17.5051 | 59.3239 | AID588544; AID588546 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 72.6538 | 0.0015 | 30.6073 | 15,848.9004 | AID1259401 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 14.1254 | 0.3758 | 27.4851 | 61.6524 | AID588526 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 33.9698 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982; AID720659 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 36.6224 | 0.0002 | 29.3054 | 16,493.5996 | AID743075; AID743077; AID743079 |
| G | Vesicular stomatitis virus | Potency | 2.1876 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 13.8029 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 20.5971 | 0.0010 | 19.4141 | 70.9645 | AID588536; AID588537; AID743094; AID743140 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 22.3347 | 0.0237 | 23.2282 | 63.5986 | AID588541; AID588543 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 14.7805 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 9.4392 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 48.0705 | 0.1434 | 27.6121 | 59.8106 | AID1159516; AID1159519 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 54.9410 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 37.8994 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 54.9410 | 0.0420 | 27.3789 | 61.6448 | AID743210 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 57.8067 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID720636 |
| Interferon beta | Homo sapiens (human) | Potency | 3.4452 | 0.0033 | 9.1582 | 39.8107 | AID1347407; AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 2.1876 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 43.4653 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID651743 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 2.1876 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 2.1876 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1112039 | Insecticidal activity against third-instar larvae of fufenozide-resistant Plutella xylostella (diamondback moth) assessed as mortality by leaf-dip bioassay method | 2012 | Pest management science, Feb, Volume: 68, Issue:2 | Cross-resistance patterns and fitness in fufenozide-resistant diamondback moth, Plutella xylostella (Lepidoptera: Plutellidae). |
| AID1112038 | Insecticidal activity against third-instar larvae of fufenozide-susceptible Plutella xylostella (diamondback moth) assessed as mortality by leaf-dip bioassay method | 2012 | Pest management science, Feb, Volume: 68, Issue:2 | Cross-resistance patterns and fitness in fufenozide-resistant diamondback moth, Plutella xylostella (Lepidoptera: Plutellidae). |
| AID1112037 | Resistance ratio, ratio of LC50 for third-instar larvae of fufenozide-resistant Plutella xylostella (diamondback moth) to LC50 for third-instar larvae of fufenozide-susceptible Plutella xylostella | 2012 | Pest management science, Feb, Volume: 68, Issue:2 | Cross-resistance patterns and fitness in fufenozide-resistant diamondback moth, Plutella xylostella (Lepidoptera: Plutellidae). |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 13 (8.02) | 18.7374 |
| 1990's | 7 (4.32) | 18.2507 |
| 2000's | 41 (25.31) | 29.6817 |
| 2010's | 70 (43.21) | 24.3611 |
| 2020's | 31 (19.14) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (2.89%) | 5.53% |
| Reviews | 1 (0.58%) | 6.00% |
| Case Studies | 3 (1.73%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 164 (94.80%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||